Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Observational Study to Evaluate the Clinical Impact of BTK Inhibitor-Based Regimens in Treatment-Naïve Patients With Mantle Cell Lymphoma (MCL) in Italian Clinical Practice.

9 november 2026 uppdaterad av: Fondazione Italiana Linfomi - ETS

An Observational Cohort Study to Evaluate the Clinical Impact of BTK Inhibitor-Based Regimens in Treatment-Naïve Patients With Mantle Cell Lymphoma (MCL) in Italian Clinical Practice.

Mantle cell lymphoma (MCL) is a subtype of B-cell non-Hodgkin lymphoma (B-NHL), characterized by a heterogeneous clinical course and, in a substantial proportion of patients, an aggressive disease behavior requiring timely and effective treatment at diagnosis.

In recent years, the therapeutic landscape of MCL has undergone a major transformation with the introduction of Bruton's tyrosine kinase inhibitors (BTKis). Ibrutinib, acalabrutinib, zanubrutinib, and the non-covalent BTKi pirtobrutinib have demonstrated substantial clinical activity in relapsed/refractry (R/R) MCL. Their role has progressively expanded beyond the relapsed/refractory setting, with BTK inhibitor-based regimens increasingly being incorporated into frontline treatment strategies, supported by emerging clinical trial evidence and reflected in evolving treatment guidelines and clinical practice.

Despite this rapidly evolving treatment landscape, real-world evidence on the use of BTKi-based regimens in the frontline setting remains limited. In particular, data on treatment selection, efficacy, safety, treatment duration, and management of toxicities in routine clinical practice are still scarce.

We therefore propose an observational cohort study to evaluate the clinical impact of previously untreated patients with MCL receiving frontline BTKi-based regimens in routine clinical practice in Italy. The study will assess treatment patterns, effectiveness, safety, and treatment persistence, providing real-world insights into the use of these strategies beyond clinical trials.

Studieöversikt

Status

Har inte rekryterat ännu

Betingelser

Studietyp

Observationell

Inskrivning (Beräknad)

500

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Previously untreated patients with Mantle Cell Lymphoma receiving frontline Bruton's Tyrosin Kinase-based treatment in routine clinical practice in Italy.

Beskrivning

Inclusion criteria:

General Inclusion Criteria:

  • Histologically confirmed diagnosis of mantle cell lymphoma (MCL) requiring treatment according to current clinical guidelines and standard-of-care recommendations.
  • Age ≥ 18 years at the time of BTKi-based treatment initiation.
  • Patients who are able to understand the nature and objectives of the study and who have provided written informed consent, approved by the Independent Ethics Committee (IEC), for participation in the observational study.

For the retrospective enrollment group:

In addition to the general inclusion criteria, patients included in the retrospective cohort must meet the following criterion:

● Patients eligible for BTKi-based treatment before the relevant marketing authorization (AIC) in Italy, includingthose treated through off-label use, compassionate use programs, or under Italian Law 648/96, as applicable.

For the prospective enrollment group:

In addition to the general inclusion criteria, patients included in the prospective cohort must meet the following criterion:

● Patients eligible for a BTKi-based regimen in accordance with the EMA-approved indication and the corresponding AIC in Italy.

Exclusion criteria:

  • Diagnosis of a histological subtype of lymphoma other than mantle cell lymphoma (MCL).
  • Concurrent participation in a prospective interventional clinical trial that may interfere with the assessment of treatment exposure, efficacy, safety, or other study endpoints.
  • Inability or unwillingness to provide written informed consent, where required by applicable ethical and regulatory requirements.
  • Any condition that, in the investigator's judgment, may preclude reliable collection or interpretation of study data or compromise the patient's ability to participate in the study.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: CROSS_SECTIONAL

Kohorter och interventioner

Grupp / Kohort
Retrospective enrollment group

Patients who had an indication for a BTKi-based regimen before the marketing authorization (AIC) in Italy. This group may include patients treated before the relevant AIC through off-label use, compassionate use programs, or treatment provided under Italian Law 648/96.

Prospective enrollment group

Patients eligible for a BTKi-based regimen in accordance with the EMA approved indication and the corresponding AIC in Italy.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Best overall response
Tidsram: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined according to Lugano 2014 criteria as the best response recorded between the start of therapy and the end of treatment. Overall response rate (ORR) includes complete (CR) and partial response (PR). Patients without response assessment for any reason are considered non-responders.

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Progression-free survival (PFS)
Tidsram: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined as the time from the start of BTKi-based treatment to the first documentation of relapse, progression or death from any cause. Patients alive without progression are censored at the date of last disease assessment.

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Overall survival (OS)
Tidsram: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined as the time from the start of BTKi-based treatment to death from any cause. Patients alive are censored at the date of last contact.

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Event-free survival (EFS)
Tidsram: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined as the time from the start of BTKi-based treatment to progression, death from any cause or initiation of a new anti-lymphoma treatment (NALT) without documented progression.

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Time to next treatment (TTNT)
Tidsram: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined as the time from the start of BTKi-based treatment to the initiation of a NALT.

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Duration of response (DOR)
Tidsram: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined in responding patients as the time from the first documentation of CR or PR to progression or death from any cause

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Non-relapse mortality (NRM)
Tidsram: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined as death without prior relapse or progression

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
POD24
Tidsram: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined as relapse or progression within 24 months from diagnosis (early POD) or later than 24 months (late POD)

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Incidence of adverse events
Tidsram: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Incidence of grade 3, 4 and 5 adverse events according to the latest NCI CTCAE version, and of serious adverse events, occurring after the first dose or at any time during therapy.

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Incidence of deaths
Tidsram: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Deaths occurring during treatment, at the end of treatment, and during follow-up, with specific assessment of early deaths (defined as deaths occurring within 3 months from treatment initiation), treatment-related (toxic) deaths, and causes of death (any).

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Treatment duration
Tidsram: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined as the time from the start of BTKi-based treatment to permanent discontinuation for any reason.

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Treatment discontinuation
Tidsram: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Incidence and reasons for treatment discontinuation (progression, toxicity, death, patient preference, physician decision, planned completion, other).

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Treatment modifications
Tidsram: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Frequency and reasons for dose reductions, interruptions and other modifications.

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Marco Ladetto, MD, S.C.D.U. Ematologia, I.R.C.C.S. A.O.U. SS. Antonio e Biagio e Cesare Arrigo - Alessandria

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 mars 2027

Primärt slutförande (Beräknad)

1 mars 2042

Avslutad studie (Beräknad)

1 mars 2042

Studieregistreringsdatum

Först inskickad

9 november 2026

Först inskickad som uppfyllde QC-kriterierna

9 november 2026

Första postat (Faktisk)

16 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

16 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

9 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera